GlaxoSmithKline Pharmaceuticals Limited has announced the launch of Carzec (carvedilol), a beta-blocker indicated in patients with heart failure and for the management of hypertension.

Hypertension or high blood pressure is a serious issue in India with studies showing a steadily increasing prevalence from 5 per cent in the 1960's to 12-15 per cent in the 1990's. There is a strong correlation between changing lifestyle factors and increase in hypertension in India. The estimated burden of hypertension in India was 118 million in 2000, with a projected increase to 213 million in 2025.

High blood pressure or hypertension is directly associated with risks of several types of cardiovascular disease but can be controlled conveniently and effectively. Carzec (carvedilol) acts by reducing the workload on the heart, thus reducing blood pressure. In addition to lowering blood pressure, Carzec has anti-oxidant and cardioprotective properties and is glucose and lipid friendly.

The launch of Carzec will be followed by a series of seminars on "Evidence based approach in the management of Heart Failure, Hypertension and co-morbidities" to be held in Chennai, Mumbai, Kolkata, Bangalore and Delhi between August 26 to 30. The symposia will be addressed by Dr Michael B. Fowler, M.B., F.R.C.P., Professor- Medicine, Director- Heart Failure Program, and Medical Director - Cardiomyopathy Center in Cardiovascular Medicine Division, at School of Medicine, Stanford University, California and will be attended by eminent cardiologists and physicians from across India.

Dr Sadhna Joglekar, vice president, medical affairs and clinical research stated, "There is tremendous potential to impact the burden of risk factors for heart disease, particularly hypertension in India. Carvedilol will provide physicians an effective option to manage patients with hypertension, as well as those with chronic heart failure. GSK is partnering with the physician community across India to develop a strong understanding of the issues surrounding under-use of beta-blockers in the management of heart failure."